Today in News History
On July 12, several notable moments in the history of News stand out. In 1884, Louis B. Mayer, Russian-born American film producer, co-founded Metro-Goldwyn-Mayer (died 1957) was born. In 1927, Harley Hotchkiss, Canadian businessman (died 2011) was born. In 1928, Elias James Corey, American chemist and academic, Nobel Prize laureate was born. In 1933, Victor Poor, American engineer, developed the Datapoint 2200 (died 2012) was born. In 1935, Satoshi Ōmura, Japanese biochemist and academic, Nobel Prize laureate was born. In 1948, Richard Simmons, American fitness trainer and actor (died 2024) was born. In 1951, Brian Grazer, American screenwriter and producer, founded Imagine Entertainment was born. In 1997, Malala Yousafzai, Pakistani-English activist, Nobel Prize laureate was born. In 2013, Alan Whicker, Egyptian-English journalist (born 1921) passed away. In 2015, Cheng Siwei, Chinese engineer, economist, and politician (born 1935) passed away. Together, these milestones provide historical context for today's news news and ongoing narratives.
Merck KGaA to Pay $11.3 Billion for Bio-Techne in Life Sciences Tools Bet
Germany's Merck KGaA agreed to pay 73 a share in cash for Bio-Techne Corp. TECH, a 36 premium valuing the Minneapolis life sciences tools group at 11.3 billion. The acquisition, the company's biggest since Sigma-Aldrich, gives Merck KGaA a catalog of 425,000 antibodies and emerging spatial biology platforms at the center of drug discovery.
Narrative Intelligence Brief
This article was published by The Eastern Herald, a source frequently categorized with a center bias based in India. Our narrative intelligence engine continuously monitors coverage from this outlet to track framing, bias, and rhetorical patterns. Our initial algorithmic scan of this specific piece did not flag high-confidence rhetorical techniques, suggesting a generally straightforward reporting style or neutral framing. By understanding the editorial perspective of The Eastern Herald, readers can better contextualize the information presented and compare it across our broader media matrix to find the real narrative.
More from The Eastern Herald
July 12, 2026
Typhoon Bavi Strikes China’s Zhejiang, 1.7 Million Evacuated as Asia Counts the Dead
July 12, 2026
Gunman Kills Two at Toronto’s Salsa on St. Clair Festival, Suspect Flees Into City
July 12, 2026
Zelensky Orders Accountability After Ukroboronprom Stored Weapons Near Kyiv Suburb Civilians
July 12, 2026
Erdogan Hosts Lebanese PM Salam in Istanbul as Turkey Seeks Post-Iran Lebanon Role
July 12, 2026
King Salman Hands Prince Abdulaziz Saudi Arabia’s Energy and Industry Portfolios
Analysis Methodology
This narrative analysis was generated using the CoDataLab Global Intelligence Engine. Our proprietary AI scans thousands of cross-border sources to identify sentiment patterns, framing techniques, and potential media bias. While AI provides the data-driven foundation, our objective is to empower readers with additional context beyond the standard headline.The content displayed above is a structured summary designed for rapid information processing. For the full original report, please visit the source outlet.More Coverage
Discussion
How other outlets are covering this story
Compare narratives across 5 related reports from 5 sources. Real Narrative News aggregates the coverage spectrum so you can see who emphasises what — bias tags reflect the outlet, not the story.
Coverage bias distribution
5 sources
Left 20%
Center 20%
Right 60%
The Eastern Herald
· Jun 26, 2026
Merck KGaA Bets $11.3 Billion on Bio-Techne and the Tools That Build Tomorrow’s Drugs
Germany's Merck KGaA is paying 11.3 billion for Minneapolis-based Bio-Techne Corp., a 36 premium that marks its biggest acquisition since Sigma-Aldrich a decade ago. The all-cash deal bets that platforms powering cell and gene therapy research will prove more durable than the therapies themselves.
ArcaMax
· Jun 26, 2026
Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history
Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth 11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, which makes lab materials and equipment used...
The Wall Street Journal - Business
· Jun 25, 2026
Germany’s Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered 73 a share in cash for Bio-Techne, representing a 24 premium to the U.S. lab-tools supplier’s closing price Wednesday.
The Motley Fool
· Jun 29, 2026
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.
Seeking Alpha
· Jun 26, 2026
Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)
Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)
Topics:
Related coverage for "Merck KGaA to Pay $11.3 Billion for Bio-Techne in Life Sciences Tools Bet": The Eastern Herald — Merck KGaA Bets $11.3 Billion on Bio-Techne and the Tools That Build Tomorrow’s Drugs. ArcaMax — Bio-Techne will be sold for $11.3B, one of largest deals in Minnesota history. The Wall Street Journal - Business — Germany’s Merck to Buy Bio-Techne for $11 Billion. The Motley Fool — What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?. Seeking Alpha — Merck KGaA: Bio-Techne Acquisition Improves Quality, But The Stock Seems Fully Valued (Downgrade)